title: Melanoma, version 4.2014.
abstract: The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.
authors.affiliation: From 1Memorial Sloan-Kettering Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Huntsman Cancer Institute at the University of Utah; 4University of Michigan Comprehensive Cancer Center; 5The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 6UC San Diego Moores Cancer Center; 7UCSF Helen Diller Family Comprehensive Cancer Center; 8Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 9St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 10University of Colorado Cancer Center; 11Aim at Melanoma; 12Dana-Farber/Brigham and Women's Cancer Center; 13Vanderbilt-Ingram Cancer Center; 14Roswell Park Cancer Institute; 15Moffitt Cancer Center; 16The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 17Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 18Fox Chase Cancer Center; 19The University of Texas MD Anderson Cancer Center; 20Duke Cancer Institute; 21Stanford Cancer Institute; 22Massachusetts General Hospital Cancer Center; 23City of Hope Comprehensive Cancer Center; 24University of Alabama at Birmingham Comprehensive Cancer Center; and 25National Comprehensive Cancer Network.
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Coit
authors.forename: John A
authors.initials: JA
authors.lastname: Thompson
authors.forename: Robert
authors.initials: R
authors.lastname: Andtbacka
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Anker
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Bichakjian
authors.forename: William E
authors.initials: WE
authors.lastname: Carson
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Daniels
authors.forename: Adil
authors.initials: A
authors.lastname: Daud
authors.forename: Dominick
authors.initials: D
authors.lastname: Dimaio
authors.forename: Martin D
authors.initials: MD
authors.lastname: Fleming
authors.forename: Rene
authors.initials: R
authors.lastname: Gonzalez
authors.forename: Valerie
authors.initials: V
authors.lastname: Guild
authors.forename: Allan C
authors.initials: AC
authors.lastname: Halpern
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Mark C
authors.initials: MC
authors.lastname: Kelley
authors.forename: Nikhil I
authors.initials: NI
authors.lastname: Khushalani
authors.forename: Ragini R
authors.initials: RR
authors.lastname: Kudchadkar
authors.forename: Julie R
authors.initials: JR
authors.lastname: Lange
authors.forename: Mary C
authors.initials: MC
authors.lastname: Martini
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Olszanski
authors.forename: Merrick I
authors.initials: MI
authors.lastname: Ross
authors.forename: April
authors.initials: A
authors.lastname: Salama
authors.forename: Susan M
authors.initials: SM
authors.lastname: Swetter
authors.forename: Kenneth K
authors.initials: KK
authors.lastname: Tanabe
authors.forename: Vijay
authors.initials: V
authors.lastname: Trisal
authors.forename: Marshall M
authors.initials: MM
authors.lastname: Urist
authors.forename: Nicole R
authors.initials: NR
authors.lastname: McMillian
authors.forename: Maria
authors.initials: M
authors.lastname: Ho
mesh_terms: D006801:Humans; D008545:Melanoma / Q000628:therapy*